Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
Posted on: Thursday, 8 January 2009, 07:00 CST
"We expect that 2009 will be a catalytic year for Poniard, as we expect to
complete enrollment in our ongoing registration trial in small cell lung
cancer. We believe the results of this trial could support an NDA filing,
leading to approval and commercialization of picoplatin in 2010," said
"Poniard is fortunate to have sufficient funding to operate the company
into 2010; a management team with a demonstrated ability to bring oncology
programs to market; and a Phase 3 oncology product currently on track for
initial commercialization in 2010," said
Poniard plans to work toward the achievement of the following picoplatin goals in 2009:
Small Cell Lung Cancer -- Complete enrollment in the ongoing Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial. This pivotal registration trial is evaluating intravenous picoplatin in SCLC patients who have failed or relapsed following initial platinum therapy within six months of initial treatment. The trial, which is being conducted under a Special Protocol Assessment (SPA) from the FDA, is evaluating overall survival as the primary endpoint. The FDA also has granted Fast-Track status, which may enable an expedited review. -- Initiate NDA filing with the U.S. Food and Drug Administration (FDA). Colorectal Cancer -- Present clinical data from the Phase 2 trial of picoplatin in patients with metastatic CRC at the American Society of Clinical Oncology's (ASCO) 2009 Gastrointestinal Cancers Symposium on January 17 in San Francisco. This randomized, controlled trial is evaluating picoplatin as a neuropathy-sparing replacement for oxaliplatin for the first-line treatment of metastatic CRC in 101 patients who have not received prior chemotherapy. The trial is comparing the safety, including neuropathy, and efficacy of intravenous picoplatin in combination with 5-fluorouracil and leucovorin (the FOLPI regimen) to oxaliplatin given in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen. -- Present updated Phase 2 clinical data, including progression-free and overall survival data from this trial, at additional medical conferences. -- Present final Phase 1 FOLPI clinical data comparing once monthly and bi-weekly picoplatin administration at key medical conferences. Hormone-Refractory or Castration-Resistant Prostate Cancer -- Present data from the ongoing Phase 2 trial of picoplatin in patients with metastatic HRPC at ASCO's 2009 Genitourinary Cancers Symposium on February 27 in Orlando, Fla. This study is evaluating the efficacy and safety of picoplatin administered every three weeks in combination with full-dose docetaxel and daily prednisone as a first- line treatment in patients with metastatic HRPC or CRPC who have not received prior chemotherapy. PSA response (defined as a PSA reduction of at least 50 percent from baseline) is the primary endpoint, and secondary endpoints include safety, tumor response rate, time to progression and overall survival. -- Present updated Phase 2 clinical data, including time to disease progression and overall survival data, at additional medical conferences. Oral Picoplatin Program -- Present final data from the Phase 1 trial of orally vs. intravenously administered picoplatin in patients with advanced solid tumor malignancies at medical conferences.About Picoplatin
Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. It is being studied in multiple cancer indications, treatment combinations and in two formulations.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.
This release contains forward-looking statements, including statements
regarding the Company's business objectives and strategic goals, drug
development plans, timing and results of clinical trials, the potential safety
and efficacy of its products in development and commercialization strategy.
The Company's actual results may differ materially from those indicated in
these forward-looking statements based on a number of factors, including risks
and uncertainties associated with the Company's research and development
activities; the results of pre-clinical and clinical testing; the receipt and
timing of FDA and other required regulatory approvals; the market's acceptance
of the Company's proposed products; the Company's anticipated operating
losses, need for future capital and ability to obtain future funding;
competition from third parties; the Company's ability to preserve and protect
intellectual property rights; the Company's dependence on third-party
manufacturers and suppliers; the Company's lack of sales and marketing
experience; the Company's ability to attract and retain key personnel; changes
in technology, government regulation and general market conditions; and the
risks and uncertainties described in the Company's current and periodic
reports filed with the Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 10-K for the year ended
(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals, Inc.
Source: PR Newswire
Related Articles
- Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
- Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 Presented at the 12th Annual Scientific Meeting of the Japanese Heart Failure Society
- Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 Presented at the 2008 Annual Heart Failure Society of America Conference
- Cytokinetics Announces Interim Clinical Trial Data Relating to CK-1827452 Presented at the European Society of Cardiology Congress 2008
- Cytokinetics Announces Clinical Trial Data Related to SB-743921 Presented at the 10th International Conference on Malignant Lymphoma
- Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
- Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be Presented at American Thoracic Society International Conference
- Large Community-Based Clinical Trial in Older Cancer Patients Suggests Benefits of Neulasta in First and Subsequent Cycles Of Chemotherapy
- A.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer Patients
- CureTech Announces Encouraging Phase I Clinical Trial Results in Cancer Patients With Its Monoclonal Antibody CT-011
 |
 |
User Comments (0)
RSS Feeds